Ratings by JMP Securities (Reni Benjamin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/3/2024 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Market Outperform (N/A) |
6.38 (5.87) |
-7.99% | Details | |
| 3/13/2024 | Prelude Therapeutics | PRLD | New Coverage | Market Outperform (N/A) |
4.09 (3.44) |
-15.89% | Details | |
| 3/1/2024 | Sana Biotechnology | SANA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/23/2024 | Inhibrx Inc. | INBX | Downgrade | Market Perform (Market Outperform) |
33.76 (34.45) |
2.04% | Details | |
| 1/10/2024 | Ambrx Biopharma | AMAM | Downgrade | Market Perform (Market Outperform) |
27.47 (28.00) |
1.93% | Details | |
| 1/5/2024 | Allogene | ALLO | Downgrade | Market Perform (Market Outperform) |
3.33 (3.46) |
3.9% | Details | |
| 12/20/2023 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/12/2023 | Sana Biotechnology | SANA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/25/2023 | Ambrx Biopharma | AMAM | New Coverage | Market Outperform (N/A) |
11.84 (28.00) |
136.49% | Details | |
| 9/25/2023 | Sana Biotechnology | SANA | New Coverage | Market Outperform (N/A) |
3.96 (7.73) |
95.2% | Details | |
| 8/23/2023 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/27/2023 | Adicet Bio Inc. | ACET | Downgrade | Market Perform (Market Outperform) |
4.73 (2.03) |
-57.08% | Details | |
| 5/5/2023 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/3/2023 | Sutro Biopharma | STRO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/27/2023 | BioAtla Inc. | BCAB | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/14/2023 | Seagen | SGEN | Downgrade | Market Perform (Market Outperform) |
172.61 (228.74) |
32.52% | Details | |
| 3/8/2023 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/2/2023 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/17/2023 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/9/2023 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/17/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/9/2022 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/15/2022 | Lava Therapeutics NV | LVTX | New Coverage | Market Outperform (N/A) |
2.46 (2.83) |
15.04% | Details | |
| 9/15/2022 | BioAtla Inc. | BCAB | New Coverage | Market Outperform (N/A) |
8.27 (2.43) |
-70.62% | Details | |
| 8/11/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/8/2022 | Compugen | CGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/5/2022 | Deciphera | DCPH | Upgrade | Market Outperform (Market Perform) |
13.57 (14.23) |
4.86% | Details | |
| 7/8/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/18/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/23/2022 | Cue Biopharma | CUE | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/2/2022 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Compugen | CGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/16/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/25/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/2/2021 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/14/2021 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/21/2021 | Inhibrx Inc. | INBX | New Coverage | Market Outperform (N/A) |
37.02 (34.45) |
-6.94% | Details | |
| 9/21/2021 | eFFECTOR Therapeutics, Inc. | EFTR | New Coverage | Market Outperform (N/A) |
19.30 (1.78) |
-90.78% | Details | |
| 8/24/2021 | Trillium Therapeutics | TRIL | Downgrade | Market Perform (Market Outperform) |
6.09 (18.44) |
202.79% | Details | |
| 5/19/2021 | Iovanace Biotherapeutics | IOVA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/20/2021 | Bicycle Therapeutics | BCYC | New Coverage | Market Outperform (N/A) |
29.45 (24.49) |
-16.84% | Details | |
| 3/19/2021 | Sutro Biopharma | STRO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Market Perform (Market Outperform) |
5.13 (0.43) |
-91.62% | Details | |
| 2/24/2021 | Seagen | SGEN | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/18/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Sutro Biopharma | STRO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/9/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Aceto Corp. | ACET | New Coverage | Market Outperform (N/A) |
12.49 (2.03) |
-83.75% | Details | |
| 10/13/2020 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/23/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/22/2020 | Seattle Genetics | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/17/2020 | Spectrum Pharmaceuticals | SPPI | New Coverage | Market Outperform (N/A) |
4.14 (1.03) |
-75.12% | Details | |
| 9/9/2020 | Trillium Therapeutics | TRIL | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/24/2020 | CTI BioPharma | CTIC | New Coverage | Market Outperform (N/A) |
1.27 (9.09) |
615.75% | Details | |
| 6/24/2020 | Constellation Pharmaceuticals | CNST | New Coverage | Market Perform (N/A) |
31.79 (33.99) |
6.92% | Details | |
| 5/31/2020 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/26/2020 | Trillium Therapeutics | TRIL | New Coverage | Market Outperform (N/A) |
6.39 (18.44) |
188.58% | Details | |
| 5/26/2020 | NextCure Inc. | NXTC | New Coverage | Market Outperform (N/A) |
33.10 (17.88) |
-45.98% | Details | |
| 5/26/2020 | Compugen | CGEN | New Coverage | Market Outperform (N/A) |
14.31 (1.88) |
-86.86% | Details | |
| 5/26/2020 | Seattle Genetics | SGEN | New Coverage | Market Outperform (N/A) |
155.77 (228.74) |
46.84% | Details | |
| 4/29/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/6/2020 | Cue Biopharma | CUE | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/22/2020 | Cue Biopharma | CUE | New Coverage | Market Outperform (N/A) |
15.40 (1.58) |
-89.74% | Details | |
| 1/14/2020 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/3/2020 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/18/2019 | Iovanace Biotherapeutics | IOVA | New Coverage | Market Outperform (N/A) |
27.50 (26.97) |
-1.93% | Details | |
| 12/18/2019 | Allogene | ALLO | New Coverage | Market Outperform (N/A) |
27.04 (3.46) |
-87.2% | Details | |
| 12/17/2019 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2019 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/22/2019 | Deciphera | DCPH | Market Outperform (N/A) |
34.23 (14.23) |
-58.43% | Details | ||
| 10/22/2019 | Blueprint Medicines | BPMC | Market Outperform (N/A) |
75.15 (88.90) |
18.3% | Details | ||
| 9/30/2019 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/5/2019 | Sutro Biopharma | STRO | New Coverage | Market Outperform (N/A) |
8.01 (3.77) |
-52.93% | Details | |
| 9/5/2019 | Kura Oncology | KURA | New Coverage | Market Outperform (N/A) |
15.24 (17.68) |
16.01% | Details | |
| 9/5/2019 | Idera Pharmaceuticals | IDRA | New Coverage | Market Outperform (N/A) |
2.60 (0.43) |
-83.46% | Details | |
| 9/5/2019 | ERYTECH Pharma SA. | ERYP | New Coverage | Market Outperform (N/A) |
5.22 (5.48) |
4.98% | Details | |
| 9/5/2019 | Incyte | INCY | New Coverage | Market Outperform (N/A) |
80.06 (52.82) |
-34.02% | Details |
